Healthcare Industry News: chronic kidney disease
News Release - June 1, 2006
Affymax Appoints Kay Slocum as Senior Vice President of Human ResourcesPALO ALTO, Calif., June 1 (HSMN NewsFeed) -- Affymax, Inc., a clinical-stage pharmaceutical company, today announced the appointment of Kay Slocum as senior vice president of human resources (HR). Ms. Slocum, who has nearly 20 years of healthcare HR experience, joins Affymax as a member of the senior management team. She will be responsible for all of the Company's HR functions, including the recruitment, management, retention, and training of employees, and administration of employee benefits.
"Kay Slocum is a seasoned HR executive with extensive experience and leadership in the biotech and healthcare industries. Her addition to our senior management team will help us increase our focus on employee development and organizational leadership," said Arlene M. Morris, president and chief executive officer of Affymax. "Kay also will help us broaden our team of highly-qualified and experienced biopharmaceutical professionals, which will be critical for us as we continue to advance our lead product candidate Hematide(TM) through clinical development and, if successful, into commercialization."
For the past three years, Ms. Slocum has served as an HR and organization effectiveness consultant for Affymax. In that position, she designed and implemented performance management systems, managed recruiting, and developed and implemented a compensation and incentive stock plan. Prior to that, she was vice president of HR for the biotech company Deltagen, Inc., where she developed HR strategies and policies to support the company's growth, the integration of acquisitions, and expansion overseas. As a vice president of HR at the biotech company Corixa Corporation (formerly Coulter Pharmaceutical), she directed the HR function during the company's growth through Phase 3 trials and the building of a sales force, and collaborated with functional leaders to strengthen the company's productivity and manage corporate partner relationships, including with GlaxoSmithKline. Earlier in her career, she served as manager of corporate employee development for Varian Associates; external management consultant for Coulter Corporation; manager of training and documentation for Teradyne Telecommunications; and manager of training and development for AM International.
She received a B.A. in sociology from Southern Illinois University and an M.S. in industrial relations from Loyola University of Chicago.
Affymax, Inc. is a clinical-stage pharmaceutical company that is developing a pipeline of synthetic peptide-based drugs against clinically validated targets for the treatment of kidney diseases and cancer. Hematide(TM), the Company's first product candidate to enter the clinic, is a novel peptide-based drug designed to stimulate the production of red blood cells. It is in Phase 2 trials for the treatment of anemia associated with chronic kidney disease and cancer. For more information go to www.affymax.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.